DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of details on the Company’s dendritic cell-based immunotherapy process, Arcelis™, as well as new research into the potential of the cytokine IL-12 as an immunopotency marker. The Company’s Arcelis™ technology is a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. Don Healey, Ph.D., Director of Immunology at Argos, will present the poster today at the 23rd Annual Meeting of the International Society for the Biological Therapy of Cancer (iSBTc).
